YOLFTbeta
Sk Biopharmaceuticals Co Ltd

Sk Biopharmaceuticals Co Ltd

326030 · KO · Healthcare / Biotechnology

87,900.00KRW+300.00 (+0.34%)

Price History

Full chart

Market Stats

Previous Close87,600.00
Open88,000.00
Day Range87,600.00 – 91,500.00
52-Week Range73,000.00 – 144,100.00
Volume159.59K
Market Cap5.94T
P/E (TTM)0.00
Forward P/E81.30
Dividend Yield0.00%
Beta0.74
50-Day Avg82,152.00
200-Day Avg97,366.50

About

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Dong Hoon Lee
  • Employees246
  • Headquarters221, Pangyoyeok-ro, Seongnam-si, South Korea, 13494, Korea
  • Websitehttps://www.skbp.com

Leadership

  • Mr. Dong Hoon LeeCEO, President & Executive Director · b. 1968
  • Mr. Jiyoung JungCFO & Executive Director · b. 1973
  • Dr. Seon-kwan HwangChief Technology Officer
  • Dr. Yong-Je ShinDirector of RPT Preclinical Center

Financials

Income Statement

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue89.93B85.32B1.10B123.85B26.00B418.64B246.18B354.89B547.60B706.74B
Growth (%)--5.13%-98.71%+11172.24%-79.01%+1510.23%-41.20%+44.16%+54.30%+29.06%
Cost of Revenue78.85B81.74B-514.20M1.97B22.34B37.77B34.08B43.10B42.90B
Gross Profit11.07B3.57B1.10B123.34B24.03B396.31B208.41B320.81B504.50B663.84B
Gross Margin12.31%4.19%100.00%99.58%92.41%94.66%84.66%90.40%92.13%93.93%
Operating Expense68.75B101.54B140.20B202.60B263.52B301.35B339.49B358.33B408.16B459.90B
Operating Income-57.67B-97.97B-139.10B-79.26B-239.50B94.96B-131.08B-37.52B96.34B203.94B
Operating Margin-64.13%-114.84%-12660.28%-63.99%-921.18%22.68%-53.24%-10.57%17.59%28.86%
EBITDA--93.61B-134.26B-76.40B-224.59B83.87B-125.77B-20.26B100.71B175.52B
EBITDA Margin--109.73%-12219.92%-61.69%-863.83%20.03%-51.09%-5.71%18.39%24.84%
Net Income-30.36B-97.65B-138.10B-71.52B-247.41B64.85B-139.43B-32.88B240.74B266.95B
Net Income Margin-33.76%-114.46%-12568.64%-57.75%-951.63%15.49%-56.64%-9.27%43.96%37.77%
R&D53.54B85.60B121.29B176.21B108.44B114.53B122.82B137.13B161.27B174.34B
R&D as % of Total Revenue59.54%100.33%11038.89%142.28%417.10%27.36%49.89%38.64%29.45%24.67%
Interest Expense0031.49M1.55B4.46B946.98M3.72B8.28B10.68B7.69B
Interest Expense % of Total Revenue0.00%0.00%2.87%1.25%17.16%0.23%1.51%2.33%1.95%1.09%

Balance Sheet

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets193.89B98.37B95.54B139.07B500.24B643.65B664.24B723.17B1.04T1.20T
Total Liabilities46.21B51.12B36.91B152.10B121.17B199.46B347.68B402.22B462.83B372.04B
Total Equity147.69B47.24B58.63B-13.03B379.07B444.19B316.56B283.69B546.27B813.04B
Cash38.61B25.27B74.29B51.14B59.33B225.92B104.06B239.70B322.81B307.77B
Net Debt---48.86B--39.66B---

Cash Flow

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-48.94B-98.34B-141.28B-81.33B-210.73B-92.87B-159.92B-94.20B94.90B176.33B
Investing Cash Flow18.37B88.40B39.46B-39.47B-318.73B258.97B-95.71B---
Financing Cash Flow----540.90B-4.65B134.91B---
Capital Expenditure8.80B1.65B1.44B14.05B11.02B4.32B4.91B3.25B13.42B29.51B
Free Cash Flow--99.99B-142.72B-95.38B-225.06B-98.86B-165.88B-97.45B81.48B146.82B
FCF to OCF-101.67%101.02%117.27%106.80%106.45%103.73%103.45%85.85%83.26%

Earnings

Report DateAug 27, 2020Nov 27, 2020Mar 9, 2021May 11, 2021Aug 9, 2021Nov 10, 2021Feb 8, 2022May 16, 2022Aug 16, 2022Nov 14, 2022Mar 9, 2023May 10, 2023Aug 14, 2023Nov 14, 2023Jan 28, 2024May 16, 2024Aug 14, 2024Nov 14, 2024Mar 7, 2025May 8, 2025Aug 14, 2025Nov 13, 2025Mar 9, 2026May 14, 2026Aug 14, 2026Nov 5, 2026
EPS Estimate-1024.54-655.73-381.092004.00-608.00-608.00-497.00-323.76-358.99-338.35-268.60-352.2365.88-333.22184.00-32.91107.24123.44197.19355.53390.33342.46434.02481.02581.55594.78
EPS Actual-913.00-805.00-727.001647.00-855.51-565.00601.77-450.00-580.00-191.00-560.00-30.00-298.00-235.0086.00164.00359.00123.002428.00298.00420.00947.001744.001343.001086.00-
Surprise10.89%-22.76%-90.77%-17.81%-40.71%7.07%221.08%-38.99%-61.56%43.55%-108.49%91.48%-552.34%29.48%-53.26%598.33%234.76%-0.36%1131.30%-16.18%7.60%176.53%301.82%179.20%86.74%-
Timing-Pre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-market----After-hoursPre-market-After-hours---Pre-marketAfter-hours-After-hoursPre-marketAfter-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap5.94T
Enterprise Value5.61T
Trailing P/E0.00
Forward P/E81.30
Price / Sales6.89
Price / Book5.82
Revenue (TTM)861.34B
Gross Profit (TTM)809.49B
EBITDA319.12B
Profit Margin46.55%
Operating Margin39.24%
Return on Equity47.92%
Return on Assets15.98%
Shares Outstanding78.31M
Shares Float39.05M
Beta0.74
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%